Neal Shore

Neal Shore is a leading urologic oncologist who has been pivotal in the development of androgen receptor pathway inhibitors for non-metastatic castration-resistant prostate cancer. He served as a principal investigator for the SPARTAN trial, which established apalutamide as a standard of care for nmCRPC. His work focuses on optimizing treatment sequencing and patient selection based on PSA doubling time. Shore has contributed extensively to clinical guidelines for nmCRPC management.